Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia

por Gotic, Mirjana, Egyed, Miklos, Gercheva, Liana, Warzocha, Krzysztof, Kvasnicka, Hans Michael, Achenbach, Heinrich, Wu, Jingyang
Publicado 2020

Screening for precapillary pulmonary hypertension in chronic myeloproliferative disorders: the role of N-terminal pro-B-type natriuretic peptide and vascular endothelial growth fac...

por Költő, Gyöngyvér, Tőkés-Füzesi, Margit, Papp, Előd, Adravetz, Zsófia, Komócsi, András, Egyed, Miklós, Faludi, Réka
Publicado 2020

Diagnostic pitfalls: intramyocardial lymphoma metastasis mimics acute coronary syndrome in a diffuse large B cell lymphoma patient—case report

por Prenek, Lilla, Csupor, Klára, Beszterczán, Péter, Boros, Krisztina, Kardos, Erika, Vorobcsuk, András, Egyed, Miklós, Kellner, Ádám, Rajnics, Péter, Varga, Csaba
Publicado 2021

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial

por Griesshammer, Martin, Saydam, Guray, Palandri, Francesca, Benevolo, Giulia, Egyed, Miklos, Callum, Jeannie, Devos, Timothy, Sivgin, Serdar, Guglielmelli, Paola, Bensasson, Caroline, Khan, Mahmudul, Ronco, Julian Perez, Passamonti, Francesco
Publicado 2018

Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial

por Montillo, Marco, Illés, Árpád, Robak, Tadeusz, Pristupa, Alexander S., Wach, Malgorzata, Egyed, Miklós, Delgado, Julio, Jurczak, Wojciech, Morschhauser, Franck, Schuh, Anna, Eradat, Herbert, Shreay, Sanatan, Barrientos, Jacqueline C., Zelenetz, Andrew D.
Publicado 2019

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis

por Harrison, Claire, Yacoub, Abdulraheem, Scott, Bart, Mead, Adam, Gerds, Aaron T., Kiladjian, Jean-Jacques, Mesa, Ruben, Egyed, Miklos, Scheid, Christof, Gutierrez, Valentin Garcia, O’Sullivan, Jennifer, Buckley, Sarah, Kanellopoulos, Kris, Mascarenhas, John
Publicado 2023

P1034: FROM SNAPSHOT TO CONTINUUM: CUMULATIVE TIME IN RESPONSE AS AN EMERGING PROXY FOR THROMBOTIC RISK IN POLYCYTHEMIA VERA

por Gisslinger, Heinz, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva-Kyuchukova, Liana, Egyed, Miklos, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Lylia, Mayer, Jiří, Yablokova, Vera, Krejcy, Kurt, Empson, Victoria, Hasselbalch, Hans C., Kralovics, Robert, Kiladjian, Jean-Jacques
Publicado 2023

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment

por Gisslinger, Heinz, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva-Kyuchukova, Liana, Egyed, Miklos, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Lylia, Mayer, Jiří, Yablokova, Vera, Krejcy, Kurt, Empson, Victoria, Hasselbalch, Hans C., Kralovics, Robert, Kiladjian, Jean-Jacques
Publicado 2023

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups

por Gisslinger, Heinz, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva-Kyuchukova, Liana, Egyed, Miklos, Rossiev, Viktor, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Lylia, Mayer, Jiri, Yablokova, Vera, Krejcy, Kurt, Hasselbalch, Hans C., Kralovics, Robert, Kiladjian, Jean-Jacques
Publicado 2020

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

por Kiladjian, Jean-Jacques, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva-Kyuchukova, Liana, Egyed, Miklos, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Lylia, Mayer, Jiří, Yablokova, Vera, Krejcy, Kurt, Empson, Victoria, Hasselbalch, Hans C., Kralovics, Robert, Gisslinger, Heinz
Publicado 2022

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia

por Newland, Adrian C., Sánchez‐González, Blanca, Rejtő, László, Egyed, Miklos, Romanyuk, Nataliya, Godar, Marie, Verschueren, Katrien, Gandini, Domenica, Ulrichts, Peter, Beauchamp, Jon, Dreier, Torsten, Ward, E. Sally, Michel, Marc, Liebman, Howard A., de Haard, Hans, Leupin, Nicolas, Kuter, David J.
Publicado 2019

Hemizygous nonsense variant in the moesin gene (MSN) leads to a new autoimmune phenotype of Immunodeficiency 50

por Kovács, András L., Kárteszi, Judit, Prohászka, Zoltán, Kalmár, Tibor, Késmárky, Gábor, Koltai, Katalin, Nagy, Zsuzsanna, Sebők, Judit, Vas, Tibor, Molnár, Krisztián, Berki, Tímea, Böröcz, Katalin, Gyömörei, Csaba, Szalma, József, Egyed, Miklós, Horváth, Szabina, Oláh, Péter, Csuka, Dorottya, Németh, Viktória, Gyulai, Rolland
Publicado 2022

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials

por Verstovsek, Srdan, Mesa, Ruben, Gupta, Vikas, Lavie, David, Dubruille, Viviane, Cambier, Nathalie, Platzbecker, Uwe, Hus, Marek, Xicoy, Blanca, Oh, Stephen T., Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Gerds, Aaron, Egyed, Miklos, Mayer, Jiří, Sacha, Tomasz, Kawashima, Jun, Morris, Marc, Huang, Mei, Harrison, Claire
Publicado 2023

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials

por Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Gerds, Aaron T., Gupta, Vikas, Verstovsek, Srdan, Egyed, Miklos, Platzbecker, Uwe, Mayer, Jiří, Grosicki, Sebastian, Illés, Árpád, Woźny, Tomasz, Oh, Stephen T., McLornan, Donal, Kirgner, Ilya, Yoon, Sung-Soo, Harrison, Claire N., Klencke, Barbara, Huang, Mei, Kawashima, Jun, Mesa, Ruben
Publicado 2023

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Contro...

por Zelenetz, Andrew D., Barrientos, Jacqueline C., Brown, Jennifer R., Coiffier, Bertrand, Delgado, Julio, Egyed, Miklós, Ghia, Paolo, Illés, Árpád, Jurczak, Wojciech, Marlton, Paula, Montillo, Marco, Morschhauser, Franck, Pristupa, Alexander S., Robak, Tadeusz, Sharman, Jeff P., Simpson, David, Smolej, Lukáš, Tausch, Eugen, Adewoye, Adeboye H., Dreiling, Lyndah K., Kim, Yeonhee, Stilgenbauer, Stephan, Hillmen, Peter
Publicado 2017

Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax

por Kotmayer, Lili, László, Tamás, Mikala, Gábor, Kiss, Richárd, Lévay, Luca, Hegyi, Lajos László, Gróf, Stefánia, Nagy, Tibor, Barna, Gábor, Farkas, Péter, Weisinger, Júlia, Nagy, Zsolt, Balogh, Alexandra, Masszi, Tamás, Demeter, Judit, Sulák, Adrienn, Kohl, Zoltán, Alizadeh, Hussain, Egyed, Miklós, Pettendi, Piroska, Gergely, Lajos, Plander, Márk, Pauker, Zsolt, Masszi, András, Matolcsy, András, Szász, Róbert, Bödör, Csaba, Alpár, Donát
Publicado 2023

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chro...

por Sharman, Jeff P., Egyed, Miklos, Jurczak, Wojciech, Skarbnik, Alan, Pagel, John M., Flinn, Ian W., Kamdar, Manali, Munir, Talha, Walewska, Renata, Corbett, Gillian, Fogliatto, Laura Maria, Herishanu, Yair, Banerji, Versha, Coutre, Steven, Follows, George, Walker, Patricia, Karlsson, Karin, Ghia, Paolo, Janssens, Ann, Cymbalista, Florence, Woyach, Jennifer A., Ferrant, Emmanuelle, Wierda, William G., Munugalavadla, Veerendra, Yu, Ting, Wang, Min Hui, Byrd, John C.
Publicado 2022

The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study

por Zijlstra, Josée M., Follows, George, Casasnovas, Rene-Olivier, Vermaat, Joost S. P., Kalakonda, Nagesh, Choquet, Sylvain, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, la Cruz, Fatima De, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo, Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Schuster, Michael, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros P., Samal, Priyanka, Ku, Matthew, Xu, Jenny, Corona, Kelly, Chamoun, Kamal, Shah, Jatin, Canales, Miguel, Maerevoet, Marie
Publicado 2022

Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

por Maerevoet, Marie, Zijlstra, Josee M., Follows, George, Casasnovas, Rene-Olivier, Vermaat, J. S. P., Kalakonda, Nagesh, Goy, Andre, Choquet, Sylvain, Van Den Neste, Eric, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, De la Cruz, Fatima, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo, Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Schuster, Michael, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros P., Samal, Priyanka, Ku, Matthew, Ma, Xiwen, Corona, Kelly, Chamoun, Kamal, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Canales, Miguel
Publicado 2021

PB1909: LOW-BURDEN TP53 MUTATIONS REPRESENT FREQUENT GENETIC EVENTS IN CLL WITH AN INCREASED RISK FOR TREATMENT INITIATION

por László, Tamás, Kotmayer, Lili, Hegyi, Lajos, Gróf, Stefánia, Kajtár, Béla, Balogh, Alexandra, Weisinger, Júlia, Masszi, Tamás, Nagy, Zsolt, Demeter, Judit, Farkas, Péter, Istenes, Ildikó, Szász, Róbert, Gergely, Lajos, Sulák, Adrienn, Borbényi, Zita, Lévai, Dóra, Schneider, Tamás, Szaleczky, Erika, Pettendi, Piroska, Bodai, Emese, Szerafin, László, Rejtő, László, Bátai, Árpád, Dömötör, Mária Ágnes, Sánta, Hermina, Plander, Márk, Szendrei, Tamás, Ilonczai, Péter, Hamed, Aryan, Lázár, Zsolt, Pauker, Zsolt, Radványi, Gáspár, Kiss, Adrienn, Körösmezey, Gábor, Jakucs, János, Dombi, Péter János, Simon, Zsófia, Klucsik, Zsolt, Gurzó, Mihály, Tiboly, Márta, Vidra, Tímea, Bors, András, Andrikovics, Hajnalka, Egyed, Miklós, Székely, Tamás, Masszi, András, Matolcsy, András, Alpár, Donát, Bödör, Csaba
Publicado 2023